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INTRODUCTION
Among patients over 80 years, 23% of those who suffer 
a stroke have atrial fibrillation, and so the number 
of patients on anticoagulation therapy is growing. 
Around one in six of these anticoagulated patients 
will require interruption of therapy for a surgical 
procedure each year.1
Perioperative management of anticoagulant therapy 
is constantly evolving, with the primary aim being a 
balance between reducing the risk of systemic arterial 
and venous embolism and reducing perioperative 
bleeding risk. The traditional strategy to ‘bridge’ 
interrupted warfarin therapy for atrial fibrillation 
with the administration of low-molecular-weight 
heparin is under review, following the results of large 
and influential studies such as the BRIDGE trial.1 
The use of novel oral anticoagulants (NOACs) is also 
increasing and so it is crucial to understand both the 
pharmacokinetics of these drugs and their use in the 
perioperative period. This article aims to give a concise 
update of perioperative anticoagulation and to guide 
readers on the perioperative management of patients 
on NOACs.
INDICATIONS FOR ANTICOAGULATION
Oral anticoagulation is indicated in the following 
conditions.
Warfarin2
• Prophylaxis of systemic embolism in patients with 
rheumatic heart disease and atrial fibrillation.
• Prophylaxis of systemic embolism after insertion 
of prosthetic heart valves.
• Prophylaxis and treatment of venous thrombosis 
and pulmonary embolism.
• Transient cerebral ischaemic attacks.
NOACs3–6
• Prevention of venous thromboembolism in 
adult patients undergoing elective hip or knee 
replacement (edoxaban not yet licensed for this 
indication).
• Prevention of stroke and systemic embolism in 
adult patients with non-valvular atrial fibrillation.
• Treatment of deep vein thrombosis and pulmonary 
embolism, and prevention of recurrent deep vein 
thrombosis and pulmonary embolism in adults.
• Rivaroxaban also licensed in acute coronary syn-
drome for prevention of artherothrombotic events 
in combination with aspirin and clopidogrel or 
ticlopidine.
CLINICAL RISK PREDICTION7
The clinical prediction tool we have used for assessing 
stroke risk factors in a patient with non-rheumatic 
atrial fibrillation during the perioperative period 
is CHADS2. Each score (0, 1, 2) represents a risk 
contributing to the likelihood of an embolic event as 
outlined in Table 1.
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Summary
Correct management of a 
patient’s anticoagulation 
during the perioperative 
period is of great 
importance.
Surgery causes 
hypercoagulability and 
most patients are at 
increased risk of venous 
thromboembolism.
Interruption of 
anticoagulation increases 
this risk further and must be 
balanced against the risk of 
surgical bleeding.
Table 1. CHADS2 tool
Risk factor Score
Congestive heart failure or left ventricular dysfunction 1
Hypertension blood pressure consist of above 140/90 mmHg or treated hypertension on medication 1
Age greater than 75 years 1
Diabetes mellitus 1
Stroke or transient ischaemic attack or thromboembolism 2
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Figure 1. A highly simplified view of the traditional clotting cascade. The sites of action of warfarin and the novel anticoagulants are shown. This 
format does conform with the information that laboratory coagulation tests provide; however, in the last 15 years, a cell-based model of coagula-
tion that better explains coagulation function and pathology that is seen in clinical practice has been proposed. Further details of this theory are 
available in the following paper: Hoffman M and Monroe DM. A cell-based model of hemostasis. Thrombosis and Haemostasis 2001; 85: 958–65
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Clinical coagulation tests commonly used for warfarin
•  Prothrombin time (PT) is the time taken (in seconds) for blood to clot in the presence of tissue factor. It assesses the extrinsic 
and common pathway of the clotting cascade and can vary depending on the situation and laboratory equipment used.
• The international normalised ratio (INR) was developed to eliminate the variation caused by different laboratories by 
comparing a PT against an internationally recognised standard PT control sample and expressing the result as a dimensionless 
ratio. Thus, an INR would be the same on a given sample regardless of the laboratory or equipment used.8
The initiation of anticoagulation is recommended in patients with 
a CHADS2 score of 2 or more.
THE CLOTTING CASCADE
The classical view of the clotting cascade (Figure 1) with intrinsic 
and extrinsic pathways has been useful for interpreting in vitro tests 
of coagulation but is felt to be outdated and potentially inaccurate. 
It is now thought that generation or exposure of tissue factors at 
the wound surface along with interaction with factor 7 is the main 
event that initiates clotting and that the cascade is much more of a 
dynamic and interwoven process.
WARFARIN
Warfarin is the most widely prescribed anticoagulant in the UK, 
and was first available in the 1950s.9 It is a vitamin K antagonist and 
inhibits the reduction of vitamin K to its active form, hydroquinone. 
16 www.wfsahq.org/resources/update-in-anaesthesia
Update in Anaesthesia ■ Volume 31 ■ June 2016
Hydroquinone binds competitively to active clotting factors 2, 7, 9 
and 10 and anticoagulant proteins C and S, decreasing their activities. 
Its effect can be measured using the prothrombin time or INR.9
Pharmacokinetics
Warfarin is almost completely absorbed from the gut with peak blood 
concentration reached within 4 hours. Peak time of action is 48–72 
hours, and anticoagulation effect generally occurs within 24 hours. 
However, peak effect may be delayed 72–96 hours.2
Side-effects
The most common side-effect of warfarin is adverse bleeding. By 
inhibiting protein C, warfarin can cause a paradoxical activation of 
coagulation, leading to thrombosis and, rarely, erythematous swollen 
skin patches, leading to ecchymosis, infarction and skin necrosis. It 
is also contraindicated in the first and third trimesters of pregnancy 
as it crosses the placenta and is teratogenic.2
Drug interactions
Warfarin interacts with multiple other drugs, particularly those 
that inhibit or induce cytochrome P450 (CYP450), as well as with 
cranberry juice. Inducers of cytochrome P450 will generally decrease 
the INR and inhibitors will increase it (Table 2).
Concomitant use of non-steroidal anti-inflammatory drugs 
(NSAIDs), including aspirin, potentiates the effect of warfarin 
through displacement of warfarin from its binding site on albumin 
and also through inhibition of platelet function.
Therapeutic use
For effective prevention of stroke, in patients in atrial fibrillation 
the time spent in the therapeutic INR range (TTR) should be 
monitored over a period of months. Ideally TTR should be greater 
than 65%. If the TTR is less than 65%, patient factors contributing 
to poor anticoagulation control should be addressed. Examples of 
such factors are:
• cognitive dysfunction
• adherence to prescribed therapy
• illness
• interacting drug therapy and
• lifestyle factors such as diet and alcohol consumption.
If no reversible factors can be identified and the TTR cannot be 
improved, an alternative method of stroke risk prevention should 
be employed.
WARFARIN BRIDGING THERAPY
Most hospitals have policies to guide bridging therapy with warfarin. 
The surgeon who books the patient for surgery should assess the need 
to interrupt anticoagulant therapy based on the bleeding risk posed 
by surgery; skin biopsies, minor dental extraction, cataract surgery 
and some cardiac procedures are associated with a low risk of bleeding 
whilst on therapeutic warfarin. Major procedures such as abdominal 
hysterectomy, endoscopic resection of prostate, lumbar discectomy, 
thyroidectomy, total joint replacement, lung operations, colonic 
resection, and radical neck dissection are high-risk operations for 
bleeding. Typically, warfarin is stopped 4–5 days prior to surgery. The 
type of bridging therapy offered is based on the patient’s thrombotic 
risk in the absence of therapeutic warfarin (see Table 3).
The BRIDGE trial1
In June 2015, the results of this randomised, double-blinded, 
placebo-controlled trial were published. The aim of the study was 
to determine if avoiding bridging in patients with atrial fibrillation 
undergoing elective procedures decreased the risk of perioperative 
bleeding and/or increased the risk of arterial thromboembolism. 
The trial included 1884 patients with atrial fibrillation (valvular and 
non-valvular) with at least one risk factor for stroke (hypertension, 
age > 75 years, congestive cardiac failure, diabetes, previous ischaemic 
stroke/transient ischaemic attack).
The results showed that, at 37 days postoperatively, there was no 
increase in thromboembolic complications but that there was a 
significant decrease in the amount of perioperative bleeding in 
patients who did not receive bridging therapy. The incidence of arte-
rial thromboembolism was 0.4% in the no-bridging group and 0.3% 
in the bridging group, a difference that was not statistically significant 
different (P = 0.01 for non-inferiority, P = 0.73 for superiority). 
Among patients who experienced arterial thromboembolism, 70% 
had undergone a minor procedure, the median time to event was 
19 days and the average CHADS2 score was 2.4.
Table 2. Common inhibitors and inducers of cytochrome P450
Inhibitors Inducers
Sodium valproate
Isoniazid
Cimetidine
Ketoconazole
Fluconazole
Alcohol
Chloramphenicol
Erythromycin
Sulphonamides
Ciprofloxacin
Omeprazole
Metronidazole
Carbamazepine
Rifampicin
Alcohol
Phenytoin
Griseofulvin
Phenobarbital
Sulphonylureas
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Major bleeding occurred in 1.3% of patients in the no-bridging 
group and in 3.2% in the bridging group.
There was no significant difference between the groups with regard 
to myocardial infarction, venous thromboembolism or death. 
The mechanisms of perioperative arterial thromboembolism may 
be closely related to factors such as the type of procedure and to 
intraoperative alterations in blood pressure. The premise that warfarin 
interruption leads to rebound hypercoagulability and that the milieu 
of the procedure confers a prothrombotic state, which in turn leads to 
arterial thromboembolism, is not supported by the results of this trial.
Limitations of the BRIDGE trial
A few groups were under-represented in the study sample, for example 
patients with CHADS2 scores of 5–6 and patients undergoing 
carotid endarterectomy, major cancer surgery, cardiac surgery and 
neurosurgery, and patients with mechanical heart valves.
Current guidance following the BRIDGE trial
For warfarinised patients with atrial fibrillation, no bridging is 
required. Bridging should be considered only if the CHADS2 score 
is greater than 4 or there is history of a CVE (including TIA) within 
the preceding 3 months.10,11
Table 3 takes into account recent updates in evidence.
PERIOPERATIVE MANAGEMENT OF THE NOACS12
The European Society of Cardiology (ESC)13 recently recommended 
that surgical procedures be classified in three categories:
• interventions not requiring discontinuation of anticoagulation 
(dental, ophthalmology procedures);
• intervention with low bleeding risk (prostate or bladder biopsy, 
angiography, pacemaker insertion);
• high bleeding risk procedures (spinal, epidural anaesthesia, 
lumbar puncture, cardiothoracic surgery, abdominal surgery, 
major orthopaedic surgery, liver biopsy, transurethral resection 
of the prostate and kidney biopsy).
The ESC guidelines advise the NOACs be stopped 24 hours before 
a low bleeding risk procedure, and between 48 and 96 hours before 
a procedure with a high bleeding risk.
DABIGATRAN
Dabigatran has predictable pharmacokinetics and can usually be 
stopped close to the time of surgery. Bridging is not currently 
recommended. Check renal function preoperatively and use results 
to plan the timing of the last dose presurgery (see Table 5).
Postoperatively, if adequate haemostasis is achieved, dabigatran can 
be restarted at the preoperative dose when haemostasis achieved. 
Alternatively, depending on the risk of a venous thrombotic event 
(VTE), prophylactic low-molecular-weight heparin (LMWH) can 
be given 6–8 hours after surgery.
RIVAROXABAN, APIXABAN AND EDOXABAN
Rivaroxaban, apixaban and edoxaban also have predictable 
pharmacokinetics and can be stopped close to the time of surgery; 
consequently, patients receiving these medications do not require 
bridging. The advice is to stop these agents 48 hours before surgery. 
Rivaroxaban/apixaban/edoxaban can be restarted at the same dose the 
patient was receiving preoperatively as soon as adequate haemostasis 
is achieved. The factor Xa inhibitor betrixaban is currently in phase 
III trials, but it is thought to have similar pharmacokinetics to other 
factor Xa inhibitors. Owing to lack of information we cannot safely 
give recommendations on stopping this anticoagulant.
REGIONAL ANAESTHESIA AND ANTICOAGULATION
Regional anaesthesia is an invaluable option for many procedures, 
either in place of or combined with general anaesthesia. Serious 
complications in patients with normal coagulation are very rare. 
For example, in the third UK national audit project, the incidence 
of vertebral canal haematoma after neuraxial blockade was 0.85 per 
100 000 cases.14 The extent to which the risk of haemorrhagic compli-
cations is increased in patients with abnormalities of anticoagulation 
is unquantifiable, but is likely to be small.15 Table 6 shows the latest 
recommendations for performing regional anaesthesia in patients on 
medications that render their coagulation abnormal.
In the UK, the Association of Anaesthetists of Great Britain and 
Ireland (AAGBI) recognises a spectrum of increased risk with 
different regional techniques. Risk relates to complications such as 
bleeding, haematomas and compression of other structures leading 
to potential airway compromise or tissue ischaemia. Epidurals and 
spinals are thought to be associated with the highest risk of complica-
tions, with the risk decreasing as the blocks become more peripheral.
ASSESSMENT OF COAGULATION WITH NOACS
Conventional tests of coagulation
The NOACs are an appealing alternative to warfarin as they do not 
need to be monitored and they have been shown to be as efficacious 
as, or indeed superior to, warfarin in preventing stroke or systemic 
embolisation. However, clinicians remain wary of these agents 
because of the lack of options for reversal of their anticoagulant 
effects in situations where this is imperative – such as emergency 
surgery and/or haemorrhage.16
The activated partial thromboplastin time (aPTT) is a measure of 
the activity of the intrinsic pathway of the coagulation cascade. 
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Table 3. Assessment of thrombotic risk and need for bridging therapy11,12
Low risk of thrombosis
Bileaflet AVR without AF, hypertension, stroke/TIA, diabetes, CCF, or age 
>75
Single VTE > 1 year ago
Atrial fibrillation with CHADS2 score of 1–4
No bridging
Check that INR on day of surgery is < 1.5
Postoperative VTE assessment for prophylaxis
Restart warfarin post operation if haemostasis adequate
Moderate risk of thrombosis
VTE > 3 months ago but < 1 year
Recurrent VTE
Active cancer (treatment < 6 months or palliative)
Bridge only if thrombotic risk > bleeding risk
If required, stop warfarin 4–5 days prior to surgery
Start prophylactic LMWH once daily 2 days after stopping warfarin
Give last dose of LMWH 24 h pre-operatively
Post operation: check adequate haemostasis
Restart LMWH 6–8 hours post-operatively (may be delayed in high-risk 
bleeding)
Continue bridging therapy until INR therapeutic
Bileaflet AVR with AF, hypertension, stroke/TIA, diabetes, CCF or age 
>75
Stop warfarin 4–5 days prior to surgery
Start therapeutic LMWH once daily 2 days after stopping warfarin
Give last dose 24 hours preoperatively
Post operation: check adequate haemostasis. Give therapeutic LMWH 
6–8 hours post-operatively (may be delayed in high-risk bleeding)
Continue bridging therapy until INR in therapeutic range
High risk of thrombosis
Mitral valve replacement
Older AVR (with tilting disc)
Any mechanical valve with stroke/TIA <6 months
Stop warfarin 5 days prior to surgery
Start therapeutic LMWH once daily 2 days after stopping warfarin
Give last dose 24 hours preoperatively
Post operation: check adequate haemostasis. Give therapeutic LMWH 
6–8 h post-operatively (may be delayed in high-risk bleeding)
Continue bridging therapy until INR in therapeutic range
AF with stroke/TIA/mitral stenosis/arterial embolism < 3 months Stop warfarin 5 days prior to surgery
Start therapeutic daily LMWH 2 days after stopping warfarin
Give last dose as a half-dose 24 hours preoperatively
Post operation: check adequate haemostasis. Give therapeutic LMWH 
at 18.00 hours on first postoperative day 
Continue bridging therapy until INR in therapeutic range
Star–Edwards (ball and cage) AVR Discuss with cardiology, as unfractionated heparin infusion may be 
required owing to high risk of thrombosis
VTE < 3 months Defer surgery if possible. If not possible, consult with haematology as 
may require therapeutic dose LMWH or an inferior vena cava filter
AF, atrial fibrillation; AVR, aortic valve replacement; CCF, congestive cardiac failure; LMWH, low molecular weight heparin; TIA, transient ischaemic 
attack; VTE, venous thrombotic event.
Whilst there is evidence that the aPTT becomes prolonged by 
dabigatran, rivaroxaban, apixaban and edoxaban, there are varying 
results depending on the reagents used and no standard calibration is 
available. It is, however, a readily available test, and a normal aPTT 
would suggest that haemostatic function is not impaired.16
The prothrombin time and international normalised ratio (INR) are 
measures of the extrinsic pathway. Warfarin is well known to increase 
the prothrombin time and its effect can be reliably measured by 
the INR. Dabigatran has been shown to have a linear relationship 
with INR; however, it is not possible to estimate the therapeutic 
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effect based on the INR and, therefore, the INR is not suitable for 
monitoring. Rivaroxaban, apixaban and edoxaban also increase 
the prothrombin time; however, again, this effect is unreliable and 
varies depending on the reagents used. Similarly to using the aPTT, 
the prothrombin time can be used as an adjunct before surgery to 
confirm if haemostatic function is impaired in patients on NOACs.16
The thrombin time reflects the activity of thrombin in the plasma. 
The amount of thrombin present and the concentration of thrombin 
inhibitors determine the time to clot formation. The thrombin time 
can be used to detect if there is any dabigatran present. There is a 
linear relationship between the thrombin time and therapeutic doses 
of dabigatran. However, at high doses the coagulometers cannot 
calculate this accurately. The test is therefore not suitable for routine 
use; however, it can be useful for testing for the presence of dabigatran 
in an emergency situation. It could be useful to check for a normal 
thrombin time in patients who are taking dabigatran and need to 
undergo a high-risk intervention such as epidural cannulation or 
neurosurgery. Rivaroxaban, apixaban and edoxaban have no effect 
on the thrombin time.16
Novel alternatives
There is slowly emerging evidence in support of the Hemoclot direct 
thrombin inhibitor assay (Hyphen BioMed, France). The test is based 
on inhibition of a constant amount of highly purified human alpha-
thrombin by adding it to diluted test plasma mixed with normal 
pooled human plasma. It has shown some accuracy in calculating the 
quantity of dabigatran present in small study populations. However, 
over the past 2 years no really convincing evidence for its accuracy 
has emerged and therefore it is not in widespread use. Cost and 
availability limit its use in low-income settings.
Table 6. AAGBI Recommendations related to drugs used to modify coagulation15
Drug
Time to peak 
effect
Elimination 
half-life
Acceptable time 
after drug for block 
performance
Administration of drug 
while spinal or epidural 
catheter in place
Acceptable time after block 
performance or catheter 
removal for next drug dose
Warfarin 3–5 days 4–5 days INR 1.4 or below Not recommended After catheter removal
Rivaroxaban prophylaxis 
(creatinine clearance 
> 30 mL min–1)
3 hours 7–9 hours 18 hours Not recommended 6 hours
Rivaroxaban treatment 
(creatinine clearance 
> 30 mL min–1)
3 hours 7–11 hours 48 hours Not recommended 6 hours
Apixaban prophylaxis 3–4 hours 12 hours 24–48 hours Not recommended 6 hours
Dabigatran prophylaxis or treatment
 Creatinine clearance > 
80 mL min–1
0.5–2 hours 12–17 hours 48 hours Not recommended 6 hours
 Creatinine clearance 
50–80 mL min–1
0.5–2 hours 15 hours 72 hours Not recommended 6 hours
 Creatinine clearance 
30–50 mL min–1
0.5–2 hours 18 hours 96 hours Not recommended 6 hours
Table 5. Using renal function to time dosing of dabigatran4
Renal function (estimated glomerular filtration rate in mL min–1) Timing of last dabigatran dose before surgery
≥ 50 2 days
30–50 4 days
≤ 30 > 5 days
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EMERGENCY REVERSAL MANAGEMENT
Assessing the severity of bleeding is the key to managing bleeding 
complications. Minor bleeding or moderate bleeding may be man-
aged symptomatically. Major and life-threatening bleeding needs to 
be managed aggressively and reversal agents, where available, should 
be considered.
Dabigatran is the only NOAC with a specific reversal agent available 
at the time of writing. Idarucizumab (Praxbind) is a monoclonal 
antibody indicated for emergency reversal of dabigatran with the 
recommended dose being 5 g and reversal effects being evident 
immediately.17 Praxbind binds to dabigatran with very high affinity. 
Binding affinity is approximately 300-fold greater than the binding 
affinity of dabigatran to thrombin.
The half-life of dabigatran after multiple doses is approximately 
14–17 hours and is not dose dependent. This makes dabigatran 
useful in patients with minor bleeding since withdrawal of the drug 
may be enough. Since the anticoagulant effect of dabigatran declines 
in parallel with its plasma concentration, urgent but not emergency 
surgery may need to be delayed for 12 hours from the last dose 
of dabigatran.18 If a specific reversal agent is not available, dialysis 
may be used for patients on dabigatran. It is expected to remove 
two thirds of dabigatran within a couple of hours.19 Rivaroxaban, 
apixaban and edoxaban are not dialysable because they are highly 
plasma protein bound.
If no specific reversal agent is available, non-specific haemostatic 
agents can be used for reversal of excessive bleeding.
• Recombinant factor 7a (NovoSeven) initiates thrombin genera-
tion by activating factor 10.
• Four-factor prothrombin complex concentrates (Beriplex, 
Octaplex) contain large amounts of non-activated vitamin 
K-dependent factors 2, 7, 9 and 10.
• Three-factor prothrombin complexes (Profilnine SD, Bebulin 
VH) contain small amounts of non-active factor 7 relating to 
2, 9 and 10.
• Activated prothrombin complex concentrate (FEIBA NF) 
contains activated factor 7 and factors 2, 9 and 10.
Studies of non-specific haemostatic agents have not concluded that 
one agent or another is better for emergency reversal. No studies have 
produced results showing complete reversal of anticoagulation using 
the measurements of aPTT, PT and thrombin time. However, use of 
non-specific haemostatic agents does reverse parts of the coagulation 
pathway. Bleeding with rivaroxaban, edoxaban and apixaban is best 
managed symptomatically with withdrawal of the drug and delaying 
of the surgery if possible. Most guidelines suggest 48 hours from 
last dose, which is around four half-lives, for necessary surgery. 
Alternatively, a regional technique could be considered. For example, 
a block could be performed 18 hours post prophylactic rivaroxaban 
dose if the patient has normal renal function.15
It should be noted that there are phase II and III trials under way 
looking at specific NOAC reversal agents. Phase III clinical trials 
with modified factor Xa (andexanet alfa) are on-going. A molecule 
with broad activity against various anticoagulants including NOACs 
(aripazine/ciraparantag) is currently undergoing phase II trials.
REVERSAL OF WARFARIN20
Warfarin reversal depends on the presentation of the patient and 
consideration should be given to the indication for warfarin in the 
patient. Where possible, procedures should be postponed if the INR 
is too high rather than routinely reversed.
The reversal agent used for warfarin is a synthetic preparation of 
phytomenadione (vitamin K1). The presence of vitamin K is essential 
for formation of prothrombin, factor 7, factor 9 and factor 10.
• Major bleeding – stop warfarin sodium; give 5 mg phytomena-
dione (vitamin K1) by intravenous injection; give four-factor 
prothrombin complex (factors 2, 7, 9 and 10); if prothrombin 
complex unavailable, fresh-frozen plasma can be given but is 
less effective.
• INR > 8.0, minor bleeding – stop warfarin sodium; give 1–3 mg 
phytomenadione (vitamin K1) by slow IV injection; repeat dose 
of phytomenadione if INR still too high after 24 hours; restart 
warfarin sodium when INR < 5.0.
• INR > 8.0, no bleeding – stop warfarin sodium; give 2.5 mg 
phytomenadione (vitamin K1) by mouth using the IV preparation 
orally; repeat dose of phytomenadione if INR still too high after 
24 hours; restart warfarin when INR < 5.0.
• INR 5.0–8.0, minor bleeding – stop warfarin sodium; give 
1–3 mg phytomenadione (vitamin K1) by IV injection; restart 
warfarin sodium when INR < 5.0.
• INR 5.0–8.0, no bleeding – withhold one or two doses of 
warfarin sodium and reduce subsequent maintenance dose.
• Unexpected bleeding at therapeutic levels – always investigate 
possibility of underlying cause, e.g. unsuspected renal or 
gastrointestinal tract pathology.
CONCLUSION
• In all patients, attention should be paid to the balance between 
the thrombotic risk posed by stopping a patient’s anticoagulation 
and the risk of bleeding.
• New evidence has shown that patients at low thrombotic risk 
can safely stop warfarin for a surgical procedure without bridging 
therapy.
• NOACs can be stopped preoperatively with no bridging because 
of their predictable and consistent pharmacokinetics. Special 
consideration should be given to dabigatran, whose excretion 
can be reduced by poor renal function.
• Thrombin time can be used to detect the presence of dabigatran 
in an emergency situation.
23www.wfsahq.org/resources/update-in-anaesthesia
Update in Anaesthesia ■ Volume 31 ■ June 2016 
• Specific emergency reversal of dabigatran is now available and 
antidotes to other NOACs are expected on the market soon.
REFERENCES
1. Douketis J, Spyropoulos A, Kaatz S. perioperative bridging 
anticoagulation in patients with atrial fibrillation. NEJM 2015; 373: 
823–33.
2. Summary of Product Characteristics: Warfarin, Taro 
Pharmaceuticals UK Ltd, May 2013. Accessed via www.medicines.
org.uk on 7 January 2016.
3. Summary of Product Characteristics: Xarelto, Bayer Plc, July 2015. 
Available at: www.medicines.org.uk (accessed 7 January 2016).
4. Summary of Product Characteristics: Pradaxa, Boehringer 
Ingelheim Ltd, Oct ober2015. Available at: www.medicines.org.uk 
(accessed 7 January 2016).
5. Summary of Product Characteristics: Eliquis, Bristol-Meyer Squibb-
Pfizer, October2015. Available at: www.medicines.org.uk (accessed 
7 January 2016).
6. Summary of Product Characteristics: Lixiana, Daiichi Sankyo UK Ltd, 
November 2015. Available at: www.medicines.org.uk (accessed 7 
January 2016).
7. National Institute for Clinical Excellence (2014) Atrial fibrillation: 
management. National Institute for Clinical Excellence. Available 
at: https://www.nice.org.uk/guidance/cg180 (accessed 8 January 
2016).
8. UpToDate 2015. Clinical use of coagulation tests. [Online]. 
Available from http://www.uptodate.com/contents/clinical-use-
of-coagulation-tests (accessed 7 January 2016).
9. British Heart Foundation. 2015. Warfarin. Available at: https://
www.bhf.org.uk/heart-matters-magazine/medical/drug-cabinet/
warfarin. (accessed 8 January 2016).
10. Royal Devon and Exeter NHS Foundation Trust. Warfarin Bridging 
Therapy. Exeter: Royal Devon and Exeter NHS Hospitals, 2015.
11. Northern Devon Healthcare NHS Trust. Perioperative 
Anticoagulation Guideline. [V1.0]. Barnstaple: North Devon District 
Hospital, 2014
12. Smith F, Telford R. Novel anti-platelet agents and anticoagulants. 
Anaesthesia Tutorial of the week 2014. [Online] Available from: www.
aagbi.org/sites/default/files/309%20Novel%20Anti-platelet%20
Agents%20and%20Anticoagulants.pdf
13. Kristensen S, Knuuti J, Saraste A. 2014 ESC/ESA Guidelines on 
non-cardiac surgery: cardiovascular assessment and management. 
European Heart Journal 2014 35: 2383–431.
14. Cook T, Counsell D, Wildsmith J. Royal College of Anaesthetists 
Third National Audit Project. Major complications of central 
neuraxial block: report on the Third National Audit Project of the 
Royal College of Anaesthetists. Br J Anaesth 2009; 102: 179–90.
15. Association of Anaesthetists of Great Britain and Ireland, Obstetric 
Anaesthetists’ Association and Regional Anaesthesia UK. Regional 
anaesthesia and patients with abnormalities of coagulation. 
Anaesthesia 2013; 68: 966–72.
16. Fawole A, Hamed D, Crowther M. Practical Management of 
bleeding due to the anticoagulants dabigatran, rivaroxaban, and 
apixaban. Cleveland Clin J Med 2013; 80: 443–51. Available at: 
http://www.frca.co.uk/article.aspx?articleid=100096
17. Summary of Product Characteristics: Praxbind, Boehringer 
Ingelheim Ltd, Dec 2015. Accessed via www.medicines.org.uk on 7 
January 2016.
18. Faraoni D, Levy J, Albaladejo P. Updates in the perioperative 
and emergency management of non-vitamin K antagonist oral 
anticoagulants. Crit Care 2015. [Online]; 19: 1–6. (accessed 17 
November 2015).
19. Kaatz S, Kouides P, Garcia D. Guidance on the emergency reversal 
of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87: 
S141–145.
20. Keeling D, Baglin T, Cambell T. Guidelines on oral anticoagulation 
with warfarin – fourth edition. Br J Haematol 2011. Blackwell 
Publishing Ltd (Guideline).
